3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Gynecologic
2
Gastrointestinal
2
Breast
2
Sarcoma
1
Other hematologic neoplasm
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Melanoma
2
Carcinoma, Renal Cell
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Interventions
pembrolizumab
23
Gemcitabine
14
Carboplatin
10
Nivolumab
9
Cyclophosphamide
9
olaparib
8
Specimen Handling
8
Paclitaxel
8
Trastuzumab
7
Magnetic Resonance Spectroscopy
6
fludarabine
5
Standard of Care
5
Irinotecan
5
Ipilimumab
5
Docetaxel
5
Cisplatin
5
Capecitabine
5
Biopsy
5
sargramostim
4
pertuzumab
4
palbociclib
4
enzalutamide
4
durvalumab
4
atezolizumab
4
aldesleukin
4
Taxes
4
Oxaliplatin
4
Fluorouracil
4
Erlotinib Hydrochloride
4
Early Intervention, Educational
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
Interleukin-15
×
Genitourinary
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled